SCHEDULE: FMR LLC Discloses 7.5% Stake in Centessa Pharmaceuticals

FMR LLC and Abigail P. Johnson have reported a combined beneficial ownership of 7.5% of Centessa Pharmaceuticals PLC's common stock as of March 31, 2026.

Summary

• FMR LLC and Abigail P. Johnson, through various subsidiaries and affiliates, collectively beneficially own 6,783,047 shares of Centessa Pharmaceuticals PLC common stock.
• This represents 7.5% of the total outstanding common stock.
• The filing is an amendment (Amendment No. 3) to a Schedule 13G, indicating a change in reporting status or holdings.
• The reporting persons are identified as investment advisers (IA) and banks (BK) through their subsidiaries FIAM LLC and Fidelity Management Trust Company, respectively.
• Abigail P. Johnson is a Director, Chairman, and CEO of FMR LLC, and members of the Johnson family are predominant owners of FMR LLC's voting shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports ownership stakes rather than company performance or strategic changes.

Positives

• Significant institutional ownership by FMR LLC and Abigail P. Johnson, indicating confidence in the company's long-term prospects.
• The filing is a routine disclosure for significant shareholders, suggesting no immediate negative event prompted the filing.

Negatives

• The filing does not contain specific financial performance data, making it difficult to assess the company's current health.
• The nature of the filing (Schedule 13G) typically relates to passive investment, but the scale of the holding warrants attention.

Risks

• Potential for future changes in FMR LLC's stake, which could impact share price.
• The filing does not detail the specific reasons for the acquisition or holding of these shares, leaving the strategic intent open to interpretation.

Future Outlook

The filing itself does not contain forward-looking statements or guidance from Centessa Pharmaceuticals PLC. It is a disclosure of ownership by FMR LLC and its affiliates.

Management Comments

• FMR LLC and Abigail P. Johnson may be deemed to be beneficial owners of the securities.
• Members of the Johnson family may be deemed to form a controlling group with respect to FMR LLC.
• This filing reflects securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the 'FMR Reporters').

Industry Context

StockSavvy.ai notes that significant stake disclosures by large investment firms like FMR LLC in pharmaceutical companies are common and can signal sustained investor interest or a strategic shift in portfolio allocation within the biotech and pharma sectors.

Stakeholder Impact

• Shareholders: The disclosure of a significant stake by FMR LLC may be viewed positively, indicating institutional support, but it does not directly impact current operations or immediate share value without further context.
• Management of Centessa Pharmaceuticals PLC: The presence of a large institutional investor like FMR LLC can influence corporate governance and strategic decisions.
• Other Investors: This filing provides transparency regarding major shareholders, aiding other investors in their analysis.

Next Steps

• Monitor future filings from FMR LLC and Centessa Pharmaceuticals PLC for any changes in ownership or strategic direction.
• Observe Centessa Pharmaceuticals PLC's performance and announcements for insights into the company's operational progress.

Key Dates

Keywords

Centessa Pharmaceuticals, FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Common Stock, Investment Management, Pharmaceuticals, SEC Filing